Prasugrel versus clopidogrel in patients with acute coronary syndromes
Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al
0 out of 10 from a total of 99 ratings on Drugs
• Works better than clopidogrel (Plavix) to lower your risk of complications after a heart attack • Taken by mouth once per day • Available as a lower-cost generic Cons • Has a
Both drugs belong to the same class of medications called platelet inhibitors
But more doctors have been using an initial, higher-than
7% in those taking aspirin; bleeding
83; 95% CI: 0
The CURE clinical
The primary efficacy endpoint of cardiac death or myocardial infarction at 6 months occurred in no patient on prasugrel versus 1 on clopidogrel
Prasugrel versus clopidogrel: new management strategies for acute coronary syndrome
With ACS, there is a lack of blood Background: Current guidelines recommend potent platelet inhibition with ticagrelor or prasugrel in patients after an acute coronary syndrome
ticagrelor, respectively , excluded patients with cardiogenic shock prior to randomization
f you are in this category a prior MI and unstable angina:" In the CAPRIE trial
In another registry in the United Kingdom, prasugrel was associated with lower adjusted 30-day mortality than ticagrelor or clopidogrel and lower adjusted 1-year mortality compared with clopidogrel
The DAPT trial compared treatment with dual antiplatelet therapy (either clopidogrel [Plavix] or prasugrel [Effient] plus aspirin) for 12 months versus 30 months in patients who had undergone The POPular AGE trial (Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome) 20 from the Netherlands randomized 1003 patients with non–ST-segment elevation myocardial infarction acute coronary syndrome above the age of 70 years to clopidogrel or a choice of either ticagrelor or prasugrel, over clopidogrel in patients with acute coronary syndrome, unless there is an excessive risk of bleeding
Prasugrel and ticagrelor are preferred over clopidogrel for patients with acute coronary syndrome who underwent percutaneous coronary intervention
Ratings & Reviews: Plavix has an average rating of 7
The average follow-up period was 143 days in the prasugrel group and 263 days in the clopidogrel group
Introduction
Awaiting head-to-head randomized trials of ticagrelor vs prasugrel, it is difficult to identify which of these two agents offers the best risk-benefit balance to overcome the limitations of clopidogrel
N Engl J Med
Clopidogrel was found to be better than The ticagrelor or prasugrel group had a lower incidence of recurrent percutaneous coronary intervention (PCI) (12
However, no differences were observed in the cumulative incidences of 3-year NACE between the ticagrelor or prasugrel and clopidogrel groups